Alan H. Bryce, MD, presented “Genetics and Biomarkers for Prostate Cancer and Bladder Cancer” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.

How to cite: Bryce, Alan H. “Genetics and Biomarkers for Prostate Cancer and Bladder Cancer” August 10th, 2020. Accessed Oct 2020. https://grandroundsinurology.com/genetics-and-biomarkers-for-prostate-cancer-and-bladder-cancer/

Summary:

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona in Scottsdale, discusses genetics and biomarkers for prostate cancer and bladder cancer. Genetic testing is now considered part of best practice for the treatment of cancer, but even still the topic can be confusing due to the number of different test types and scenarios. In order to combat this confusion, it is important that urologists continue to educate themselves on the matter. Dr. Bryce discusses the purpose of using either germline or somatic tests and the different information they can tell us. He goes into particular detail about the somatic test and how useful it can be in determining which targeted therapies to use for both prostate and bladder cancer. Finally, he also offers some advice on best practices for utilizing the somatic test including: testing every patient, always using a fresh biopsy, and retesting before each line of systemic therapy.

About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Bryce presented this lecture during this year’s virtual conference in August 2020.